Divergent Transcriptomic Effects of Allopregnanolone in Postpartum Depression

Brexanolone, a formulation of the neurosteroid allopregnanolone (ALLO), is approved for treating postpartum depression (PPD) and is being investigated for therapeutic efficacy across numerous neuropsychiatric disorders. Given ALLO’s beneficial effects on mood in women with PPD compared to healthy co...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudzinskas, Sarah A., Mazzu, Maria A., Schiller, Crystal Edler, Meltzer-Brody, Samantha, Rubinow, David R., Schmidt, Peter J., Goldman, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298697/
https://www.ncbi.nlm.nih.gov/pubmed/37372414
http://dx.doi.org/10.3390/genes14061234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298697/
https://www.ncbi.nlm.nih.gov/pubmed/37372414
http://dx.doi.org/10.3390/genes14061234

Ejemplares similares